SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Piramal: $53m Ash Stevens addition ‘synergistic’ with ADC business

18-Aug-2016 - The acquisition of Ash Stevens and a US high potent API facility will bolster Piramal’s antibody-drug conjugate offerings, the Indian CDMO says.

Public Patheon's $2bn warchest may bolster biologics offering, analyst

17-Aug-2016 - Biomanufacturing demand will drive revenues for Patheon according to an Evercore ISI analyst, who has predicted the newly-listed CDMO will strengthen its capabilities through M&A.

Pfizer halts production at Hospira India plant slammed by regulators

09-Aug-2016 - Pfizer has temporarily halted production at a former-Hospira aseptic plant in Chennai, India after regulators observed manufacturing issues during an inspection in June.

News in brief

Biesterfield buys fellow API distributor Schütz

02-Aug-2016 - Biesterfeld says the acquisition of fellow Germany-based distributor Schütz strengthens the firm’s focus on specialty chemicals.

Pfizer takes axe to Hospira network, exiting 'under-utilised' Colorado plant

27-Jun-2016 - Over 100 Colorado jobs could be lost following Pfizer’s decision to exit a former Hospira API plant by 2019.

Monsanto bid may mean Bayer will cut pharma R&D spending, says analyst

31-May-2016 - The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

Pfizer, Anacor enter into merger agreement

18-May-2016 - Pfizer and Anacor Pharmaceuticals have entered into a definitive merger agreement under which Pfizer will acquire Anacor for approximately $5.2bn.

Endo takes axe to Par manufacting network: 740 jobs affected

12-May-2016 - Endo International says it intends to expedite a cost-saving plan by closing a manufacturing site in North Carolina and reducing headcount at another in Alabama.

Ferrer to add drug aerosol delivery tech through Alexza acquisition

11-May-2016 - Grupo Ferrer Internacional will acquire Alexza Pharmaceuticals for around $2m, adding the Staccato aerosol system to its drug delivery offerings.

AMRI acquires API business, expands into Europe

05-May-2016 - AMRI has acquired the Italy-based chemical company, Euticals, in a move that expands its API development and manufacturing business.

Biogen haemophilia spin-out to develop gene therapies and long-acting factors

04-May-2016 - The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.

Return to growth: Pfizer thanks Hospira and looks to biosimilars

04-May-2016 - Pfizer has attributed Hospira’s sterile injectables and biosimilar assets to its return to growth, offsetting 17 quarters of declining sales.

Lonza would add drug delivery tech through Catalent merger, analyst

14-Apr-2016 - Lonza acquiring Catalent would make “strategic sense,” according to an analyst as rumours circulate about a CMO megamerger.

Capsugel ripe to be sold or go public, investment banker

30-Mar-2016 - Rumours Capsugel owner KKR is mulling a sale or an IPO fit with the typical private equity investment cycles says expert.

Blu buy bolsters Puracap in US softgel market

29-Mar-2016 - Puracap has bought Blu Pharmaceuticals and its Puerto Rican manufacturing site and plans to double oral dose production capacity.

M&A strategy paying off for AMRI; more API acqs to come

18-Feb-2016 - Controlled substances and peptides are on AMRI’s wish list as it profits from a growth strategy which has seen six acquisitions over the past two years.

Pfizer and Allergan to mull splitting up again in 2018 say CEOs

13-Jan-2016 - The Pfizer-Allergan $160bn merger will create the world’s largest pharma company but potentially not for long, as the two CEOs discuss breaking the entity up in 2018.

Sun selling Ohio plant in post-Ranbaxy network restructure

15-Dec-2015 - Sun Pharma has announced it will divest a plant in Ohio to further consolidate manufacturing operations following its $4bn acquisition of Ranbaxy.

Pfizer-Allergan merger

‘Over 90%’ of industry thinks Pfizer will sell generics biz

30-Nov-2015 - Pfizer says it will decide in 2018 whether to split its generics and branded businesses but M&A experts are already predicting how the giant will get rid of its established...

Pfizer-Allergan combo would comprise 100+ sites and post-Wyeth level headcount

12-Nov-2015 - Pfizer’s manufacturing network would stretch beyond 100 sites if a merger deal with Allergan is reached.

Unilife undecided on takeover plans; gives December 31 deadline

10-Nov-2015 - Unilife CEO Alan Shortall yesterday confirmed the drug delivery company is still “receiving interest from several parties under the strategic review process” and set a deadline of December 31 to...

Acquisitions drive AMRI’s ambition to become a ‘billion dollar’ CDMO

09-Nov-2015 - AMRI attributed recent M&A activity to passing the $100m (€93m) quarterly sales milestone, reporting high double-digit growth across its API and small-scale manufacturing divisions.

CPhI Worldwide 2015

Rush to acquire ex-pharma sites means survival of the biggest for CMOs

22-Oct-2015 - As pharma sells off manufacturing capacity and outsources to large and specialist CMOs, smart contract houses will have an opportunity to grab market share in a currently fragmented sector, say...

CPhI Worldwide 2015

After the M&A bubble bursts: the four types of pharma firm to survive

21-Oct-2015 - An advisor to the pharma industry on M&A says the current boom in pharma valuations will not last, and R&D cost pressures will reshape firms of the future....

M&A

Sun Pharma eyes US ocular delivery expert

16-Sep-2015 - Indian generics company Sun Pharma has made a $48m (€42m) offer for US eye drug maker InSite Vision and its delivery platform.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...